AUTHOR=Li Jianglei , Yu Meihong , Fu Shifeng , Liu Deliang , Tan Yuyong 

TITLE=Role of Selective Histone Deacetylase 6 Inhibitor ACY-1215 in Cancer and Other Human Diseases

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 13 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.907981

DOI=10.3389/fphar.2022.907981

ISSN=1663-9812

ABSTRACT=The deacetylation process regulated by histone deacetylases (HDACs) plays an important role in human health and diseases. HDAC6 belongs to the class-IIb of HDACs family, which can not only modify histone modification, but also non-histone proteins located in the cytoplasm. HDAC6 plays a key role in tumors, neurological diseases, and inflammatory diseases. Therefore, the treatment targeting HDAC6 has become a promising new direction in recent years. ACY-1215 is the first orally available highly selective HDAC6 inhibitor, and its efficacy and therapeutic effect are being continuously verified. This article summarizes the research progress of ACY-1215 and the corresponding pathway, in order to guide the future clinical trials of ACY-1215 and more in-depth mechanism research.